News Focus
News Focus
icon url

DewDiligence

01/14/11 12:48 PM

#112569 RE: DewDiligence #112548

The primary beneficiary of ABT’s mishap with Briakinumab is JNJ’s Stelara, which has been a commercial disappointment to date.